The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding

2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2019) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation

(2018) Jung-Im Shin et al.   Clinical Journal of the American Society of Nephrology

Safety of apixaban in combination with dronedarone in patients with atrial fibrillation

(2018) Leif Friberg   INTERNATIONAL JOURNAL OF CARDIOLOGY

Rivaroxaban With and Without Amiodarone in Renal Impairment

(2018) Eleanor Jing Yi Cheong et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban

(2018) Ping G. Tepper et al.   PLoS One

Association Between Use of Non–Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation

(2017) Shang-Hung Chang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa

(2016) Blisse Vakkalagadda et al.   American Journal of Cardiovascular Drugs

Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor

(2015) Charles E. Frost et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Dabigatran and Rivaroxaban Use in Atrial Fibrillation Patients on Hemodialysis

(2015) K. E. Chan et al.   CIRCULATION

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

(2015) Ming Chang et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

(2015) S. Kaatz et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: Results from the ROCKET AF trial

(2014) Benjamin A. Steinberg et al.   HEART RHYTHM

An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function

(2014) Kenneth T. Moore et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Amiodarone, Anticoagulation, and Clinical Events in Patients With Atrial Fibrillation

(2014) Greg Flaker et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects

(2013) Wolfgang Mueck et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban

(2011) M. J. Gnoth et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor

(2010) Dagmar Kubitza et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients

(2009) S. SCHULMAN et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS